Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial) - Provencio, M; Serna-Blasco, R; Nadal, E (J Clin Oncol, 2022)